Phagos Leads Charge Against Antibiotic Resistance with €25M Boost
October 13, 2025, 3:42 pm
Paris-based Phagos secured €25 million in Series A funding to propel its AI-driven bacteriophage therapies. This biotech pioneer confronts antimicrobial resistance, a critical global health crisis. Phagos initially focuses on animal health, having obtained the EU's landmark authorization for personalized veterinary phage treatments. The significant investment will accelerate the deployment of these innovative solutions, advance its patented AI discovery technology, and fuel ambitious international expansion across Europe, Asia, and the Americas. Phagos seeks to establish phage therapy as a scalable, targeted, and effective alternative to dwindling antibiotic efficacy, promising a revolution in treating bacterial infections for animals today and humans tomorrow.
Phagos, a cutting-edge Paris-based biotechnology company, has closed a pivotal €25 million Series A funding round. This substantial capital injection empowers its bold mission. The company aims to redefine how bacterial infections are combated. Phagos pioneers advanced bacteriophage-based therapies. These natural microscopic agents offer a powerful, sustainable alternative to traditional antibiotics. Its innovative platform marries microbiology with artificial intelligence.
The global health landscape faces an urgent threat: antimicrobial resistance (AMR). Bacterial infections represent the world's second leading cause of human mortality. They are a major driver of animal deaths. AMR already claims millions of lives annually. Economic models predict staggering losses. The global economy could hemorrhage up to $100 trillion by 2050 due to AMR. This crisis extends beyond human hospitals. It profoundly impacts livestock and agriculture. One in three antibiotics is now ineffective in animals. This marks a dramatic threefold increase since 2000. This escalating resistance fuels food waste. It generates immense economic losses across the food supply chain. New, effective solutions are not just desirable; they are imperative.
Phagos was founded in 2021. Its vision, championed by Alexandros Pantalis and Dr. Adèle James, was clear. They sought to leverage nature’s precision against pathogens. Bacteriophages, often called "bacteria eaters," are viruses. They specifically target and destroy harmful bacteria without harming host cells. Phagos has transformed this natural phenomenon. It created a scalable, targeted therapeutic platform. Its core innovation lies in its patented AI technology. This sophisticated system meticulously analyzes bacterial and phage genomes. It predicts their intricate interactions with unparalleled accuracy. This predictive power allows for the design of ultra-precise, personalized phage treatments. It ensures efficacy. It also enables broad applicability.
The company's strategic entry point is animal health. This sector provides a critical proving ground. It offers immense market need. Livestock frequently suffers from severe bacterial infections. Pathogens like Salmonella and E. coli cause widespread disease. They lead to significant productivity losses. Phagos's initial solutions directly address these pervasive issues. The success in animal health lays groundwork for future expansion.
Phagos has already achieved a landmark regulatory breakthrough. It became the first company globally authorized to market personalized phage-based veterinary treatments. This approval came from the European Union. This regulatory validation is monumental. It confirms the safety and efficacy of its pioneering approach. This achievement establishes a clear pathway. It paves the way for widespread commercial deployment of phage therapies. It underscores a shift in regulatory acceptance. It signals a new era for alternative antimicrobial solutions.
The recent €25 million Series A funding round underscores investor confidence. It highlights the transformative potential of Phagos. The round saw co-leadership from CapAgro, Hoxton Ventures, CapHorn, and Demeter. Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F also contributed. This broad base of support fuels aggressive growth.
This capital injection will drive several key initiatives. Phagos will significantly expand the deployment of its veterinary phage therapy solutions. This expansion will reach new markets. The company plans ambitious international growth. It targets key regions including Europe, Asia, and the Americas. Research and development efforts will intensify. This pushes the boundaries of its proprietary AI technology. The goal is to develop the next generation of its discovery platform. This enhanced AI will unlock even greater therapeutic precision. The Phagos team, already highly specialized, will also grow. Over 90% of its current staff are scientific and technical professionals. New hires will bolster market launches. They will accelerate product development pipelines. Phagos is actively forming strategic collaborations. It partners with major industry players. These partnerships facilitate field deployments. They expand market reach.
The long-term vision for Phagos is expansive. It aims to establish phage therapy as a global reference solution. This will fundamentally reshape bacterial infection treatment. The company believes phage therapy can revolutionize medicine. Its impact could mirror that of antibiotics in the last century. Today, the focus is on animal health. Tomorrow, these innovations will extend to human health. Phagos offers a beacon of hope. It provides a sustainable, effective answer to a deepening global health crisis. This investment marks a pivotal moment. It signifies robust commitment to deep tech innovations. These innovations are essential. They foster healthier, more resilient food systems. Phagos stands poised to lead this medical transformation. It delivers a high-efficiency alternative. It offers a promising future for combating bacterial pathogens worldwide.
Phagos, a cutting-edge Paris-based biotechnology company, has closed a pivotal €25 million Series A funding round. This substantial capital injection empowers its bold mission. The company aims to redefine how bacterial infections are combated. Phagos pioneers advanced bacteriophage-based therapies. These natural microscopic agents offer a powerful, sustainable alternative to traditional antibiotics. Its innovative platform marries microbiology with artificial intelligence.
The global health landscape faces an urgent threat: antimicrobial resistance (AMR). Bacterial infections represent the world's second leading cause of human mortality. They are a major driver of animal deaths. AMR already claims millions of lives annually. Economic models predict staggering losses. The global economy could hemorrhage up to $100 trillion by 2050 due to AMR. This crisis extends beyond human hospitals. It profoundly impacts livestock and agriculture. One in three antibiotics is now ineffective in animals. This marks a dramatic threefold increase since 2000. This escalating resistance fuels food waste. It generates immense economic losses across the food supply chain. New, effective solutions are not just desirable; they are imperative.
Phagos was founded in 2021. Its vision, championed by Alexandros Pantalis and Dr. Adèle James, was clear. They sought to leverage nature’s precision against pathogens. Bacteriophages, often called "bacteria eaters," are viruses. They specifically target and destroy harmful bacteria without harming host cells. Phagos has transformed this natural phenomenon. It created a scalable, targeted therapeutic platform. Its core innovation lies in its patented AI technology. This sophisticated system meticulously analyzes bacterial and phage genomes. It predicts their intricate interactions with unparalleled accuracy. This predictive power allows for the design of ultra-precise, personalized phage treatments. It ensures efficacy. It also enables broad applicability.
The company's strategic entry point is animal health. This sector provides a critical proving ground. It offers immense market need. Livestock frequently suffers from severe bacterial infections. Pathogens like Salmonella and E. coli cause widespread disease. They lead to significant productivity losses. Phagos's initial solutions directly address these pervasive issues. The success in animal health lays groundwork for future expansion.
Phagos has already achieved a landmark regulatory breakthrough. It became the first company globally authorized to market personalized phage-based veterinary treatments. This approval came from the European Union. This regulatory validation is monumental. It confirms the safety and efficacy of its pioneering approach. This achievement establishes a clear pathway. It paves the way for widespread commercial deployment of phage therapies. It underscores a shift in regulatory acceptance. It signals a new era for alternative antimicrobial solutions.
The recent €25 million Series A funding round underscores investor confidence. It highlights the transformative potential of Phagos. The round saw co-leadership from CapAgro, Hoxton Ventures, CapHorn, and Demeter. Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F also contributed. This broad base of support fuels aggressive growth.
This capital injection will drive several key initiatives. Phagos will significantly expand the deployment of its veterinary phage therapy solutions. This expansion will reach new markets. The company plans ambitious international growth. It targets key regions including Europe, Asia, and the Americas. Research and development efforts will intensify. This pushes the boundaries of its proprietary AI technology. The goal is to develop the next generation of its discovery platform. This enhanced AI will unlock even greater therapeutic precision. The Phagos team, already highly specialized, will also grow. Over 90% of its current staff are scientific and technical professionals. New hires will bolster market launches. They will accelerate product development pipelines. Phagos is actively forming strategic collaborations. It partners with major industry players. These partnerships facilitate field deployments. They expand market reach.
The long-term vision for Phagos is expansive. It aims to establish phage therapy as a global reference solution. This will fundamentally reshape bacterial infection treatment. The company believes phage therapy can revolutionize medicine. Its impact could mirror that of antibiotics in the last century. Today, the focus is on animal health. Tomorrow, these innovations will extend to human health. Phagos offers a beacon of hope. It provides a sustainable, effective answer to a deepening global health crisis. This investment marks a pivotal moment. It signifies robust commitment to deep tech innovations. These innovations are essential. They foster healthier, more resilient food systems. Phagos stands poised to lead this medical transformation. It delivers a high-efficiency alternative. It offers a promising future for combating bacterial pathogens worldwide.